2023 Cancer Immunotherapy Summit: Everything, Everywhere, All At Once of Cancer Immunotherapy

Coeur d'Alene, ID US
September 22, 2023 to September 23, 2023

This CME-accredited conference, "2023 Cancer Immunotherapy Summit: Everything, Everywhere, All At Once of Cancer Immunotherapy" features leading experts in the field who will provide a comprehensive overview of current and emerging strategies to integrate immunotherapy in the management of cancers. These experts will offer their insights on mechanisms of immunotherapy toxicity, host factors regulating efficacy and resistance, and neoadjuvant immunotherapy, all in the pursuit of improving patient outcomes. This activity aims to enhance learners' knowledge and competence to apply practice-changing clinical data and expert recommendations to incorporate immunotherapy and optimize clinical outcomes for cancer patients. The oncology conference will use a mix of didactic lectures and case-based panel discussions to highlight areas of debate in the field of immuno-oncology. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to contribute effectively to patient care.

Target Audience

  • Medical oncologists

  • Hematologist oncologists

  • Oncology/Hematology residents/fellows

  • Oncology NPs/PAs

  • Oncology pharmacists

  • Oncology nurses

Learning Objectives

  • Review mechanisms of action of currently approved and emerging immunotherapies
  • Review indications and outcomes of approved immunotherapies.
  • Identify and manage complications of immunotherapies.
  • State the financial, physical, and other barriers, and review strategies to navigate these factors to optimize the management of patients with immunotherapies.
  • Discuss novel neoadjuvant and adoptive therapies in the management of cancers.
  • Incorporate biomarkers in the management plan of cancers. 

You may also be interested in

Santa Fe Precision Oncology Symposium

This program, the Santa Fe Precision Oncology Symposium, is an accredited continuing education activity designed to improve the care of cancer patients by educating cancer care providers about precision oncology.
2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes

The 2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes is an oncology conference featuring leading experts in the field of precision oncology who will provide a comprehensive overview of the implications of actionable molecular alterations

Course summary
Available credit: 
  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.
Course opens: 
05/25/2023
Course expires: 
12/22/2023
Event starts: 
09/22/2023 - 3:00pm PDT
Event ends: 
09/23/2023 - 5:30pm PDT
Cost:
$150.00
Add to calendar: 

Conference Chair: Shailender Bhatia, MD

DAY 1 – September 22, 2023

All times are listed in Pacific Daylight Time (PDT)

02:00 PM – 03:00 PM  REGISTRATION, NETWORKING, EXHIBITS

03:00 PM – 03:10 PM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA

03:10 PM – 05:55 PM  SESSION 1 – IMMUNOTHERAPY MODALITIES: MECHANISMS OF ACTION                                                     

Session Chair: Shailender Bhatia, MD

03:10 PM - 03:15 PM  Welcome and Pre Test

03:15 PM - 03:40 PM  Immune-Checkpoint Inhibitors: Old and New - Adil Daud, MD

03:40 PM - 04:05 PM  Adoptive T-Cell Therapy: What is on the Horizon? - Aude Chapuis, MD

04:05 PM - 04:30 PM  Repurposing Radiation Therapy for Immune Stimulation - Peter Goff, MD, PhD

04:30 PM - 04:55 PM  Harnessing Innate Immunity (NK cells, TLRs, MDSCs etc..) - Kevin Barry, PhD

04:55 PM - 05:00 PM  Post-test 

05:00 PM - 05:55 PM  Panel Discussion: Financial Toxicity of IO Agents and Access to Cellular Therapy - Nathanael Gay, MD; Hiba Khan, MD, MPH; Raj Rajendra, MD

DAY 2 - September 23, 2023

07:00 AM - 7:55 AM  REGISTRATION, BREAKFAST, EXHIBITS

08:00 AM - 10:00 AM  SESSION 2 – UPDATES IN CANCER IMMUNOTHERAPY (PART 1)

Session Chair: Kelly Paulson, MD, PhD

08:00 AM - 08:10 AM  Welcome and Pre-Test 

08:10 AM - 08:35 AM  Skin Cancers (Melanoma and Non-Melanoma) - Diwakar Davar, MD

08:35 AM - 09:00 AM  Lung Cancer - Smitha Menon, MD

09:00 AM - 09:25 AM  Women's Cancers (Breast, Gynecologic Malignancies) - Kalyan Banda, MD

09:25 AM - 09:30 AM: Post-test

09:30 AM - 10:00 AM  Panel Discussion: Duration of ICI Therapy in Responding to Patients - Sid Devarakonda, MBBS, MD; Paul White, MD

10:00 AM - 10:30 AM  BREAK, EXHIBITS, NETWORKING

10:30 AM - 12:00 PM  SESSION 3 – IMMUNOTHERAPY BIOMARKERS

Session Chair: Shailender Bhatia, MD

10:30 AM - 10:35 AM  Pre-test

10:35 AM - 11:00 AM  PD-L1, TILS, and Other Immune-Related Biomarkers - Kartik Sehgal, MD

11:00 AM - 11:25 AM  Microbiome - Diwakar Davar, MD

11:25 AM - 11:50 AM  TMB - Vera Paulson, MD, PhD

11:50 AM - 12:00 PM  Post-test

12:00 PM - 01:00 PM  LUNCH, EXHIBITS, NETWORKING

01:00 PM - 01:45 PM  KEYNOTE LECTURE - Cancer Vaccines: The Future is Bright - Nora Disis, MD

01:45 PM - 02:45 PM  SESSION 4 – UPDATES IN CANCER IMMUNOTHERAPY (PART 2)

Session Chair: Shailender Bhatia, MD

01:45 PM - 01:50 PM  Pre-test

01:50 PM - 02:15 PM  Urothelial Cancer - Sandy Srinivas, MD

02:15 PM - 02:40 PM  Renal Cell Carcinoma - Scott Tykodi, MD, PhD

02:40 PM - 02:45 PM  Post-test

02:45 PM - 03:15 PM  BREAK & EXHIBITS

03:15 PM - 05:45 PM  SESSION 5 – IMMUNE-RELATED ADVERSE EVENTS

Session Chair: John Thompson, MD

03:15 PM - 03:20 PM  Pre-test 

03:20 PM - 03:45 PM  Colitis - Yinghong Wang, MD, PhD, MS

03:45 PM - 04:10 PM  Rheumatologic Toxicities - Namrata Singh, MD, MSCI, FACP

04:10 PM - 04:35 PM  Nephritis - Abbal Koirala, MD

04:35 PM - 05:00 PM  Dermatologic Toxicities - Ata Moshiri, MD, MPH

05:00 PM - 05:05 PM  Post-test 

05:05 PM - 05:45 PM  Panel Discussion: Use of ICIs in Pre-Existing Autoimmunity/Organ Transplant/Prior IRAEs - Lei Deng, MD; Joe Rosales, MD

05:45 PM - 05:50 PM  Concluding Remarks

Coeur d'Alene Resort
115 S 2nd St
Coeur d'Alene, ID 83814
United States

A limited number of rooms have been booked for the attendees and faculty of this meeting at the Coeur d'Alene Resort at the discounted rate listed below. Please call into the Resort's reservations department at 888-965-6542, mention Binaytara, and make your room reservations. 

 

 

Travel

The Coeur d'Alene Resort offers a shuttle from/to the Spokane airport for $79 per person round-trip. Please call the hotel to make a reservation.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Shailender Bhatia, MD

has a financial relationship (Grant Or Contract) with Bristol Meyers Squibb;.
has a financial relationship (Grant Or Contract) with Immune Design;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Professional Services) with Regeneron/Sanofi;.
has a financial relationship (Grant Or Contract) with Amphivena;.
has a financial relationship (Grant Or Contract) with Exicure;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Xencor;.
has a financial relationship (Grant Or Contract) with Agenus;.
has a financial relationship (Grant Or Contract) with EMD Serono;.
has a financial relationship (Grant Or Contract) with Kuni Foundation;.
has a financial relationship (Grant Or Contract) with Trisalus Life Sciences;.
has a financial relationship (Grant Or Contract) with 4SC;.
has a financial relationship (Grant Or Contract) with Regeneron (fka Checkmate Pharmaceuticals);.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Novartis;.
Moderator(s)

Kelly Paulson, MD, PhD

has no relevant financial relationships to disclose at this time.

John Thompson

has a financial relationship (Independent contractor) with Mabquest;.
Planner(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Speaker(s)

Kalyan Banda

has a financial relationship (Other) with MorphoSys;.
has a financial relationship (Other) with Eli Lily ;.

Kevin Barry, PhD

has no relevant financial relationships to disclose at this time.

Shailender Bhatia, MD

has a financial relationship (Grant Or Contract) with Bristol Meyers Squibb;.
has a financial relationship (Grant Or Contract) with Immune Design;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Professional Services) with Regeneron/Sanofi;.
has a financial relationship (Grant Or Contract) with Amphivena;.
has a financial relationship (Grant Or Contract) with Exicure;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Xencor;.
has a financial relationship (Grant Or Contract) with EMD Serono;.
has a financial relationship (Grant Or Contract) with Kuni Foundation;.
has a financial relationship (Grant Or Contract) with Trisalus Life Sciences;.
has a financial relationship (Grant Or Contract) with Agenus;.
has a financial relationship (Grant Or Contract) with Regeneron (fka Checkmate Pharmaceuticals);.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with 4SC;.

Aude Chapuis, MD.

has a financial relationship (Grant Or Contract) with Cullinan;.
has a financial relationship (Other Business Ownership) with SignalOne Bio;.
has a financial relationship (Grant Or Contract) with Bluebird Bio;.
has a financial relationship (Grant Or Contract) with EMD Serono;.
has a financial relationship (Other) with Metagenomi;.
has a financial relationship (Grant Or Contract) with Juno Therapeutics;.
has a financial relationship (Grant Or Contract) with Lonza;.
has a financial relationship (Other) with Tscan;.
has a financial relationship (Grant Or Contract) with Amazon;.
has a financial relationship (Other Business Ownership) with Affini-T Therapeutics;.

Adil Daud, MBBS

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with merck;.
has a financial relationship (Professional Services) with regeneron;.

Diwakar Davar, MD

has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Immunocore;.
has a financial relationship (Grant Or Contract) with Cellsight Technologies;.
has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Arcus;.
has a financial relationship (Grant Or Contract) with Regeneron Pharmaceuticals Inc.;.

Lei Deng, MD

has a financial relationship (Other) with MJH Life Sciences;.
has a financial relationship (Travel) with MJH Life Sciences;.

Siddhartha Devarakonda, MBBS, MD

has a financial relationship (Other) with Merus;.
has a financial relationship (Other) with Genetech;.
has a financial relationship (Other) with AZ;.
has a financial relationship (Other) with Jazz;.

Mary Disis

has a financial relationship (Grant Or Contract) with Bavarian Nordic;.
has a financial relationship (Grant Or Contract) with Aston Sci;.
has a financial relationship (Grant Or Contract) with Precigen;.
has a financial relationship (Grant Or Contract) with Veanna;.

Nathan Gay, MD

has no relevant financial relationships to disclose at this time.

Peter Goff, MD PhD

has a financial relationship (Grant Or Contract) with Gilead Sciences Inc.;.

Hiba Khan, MD, MPH

has no relevant financial relationships to disclose at this time.

Abbal Koirala, MD

has no relevant financial relationships to disclose at this time.

Smitha Menon

has no relevant financial relationships to disclose at this time.

Ata Moshiri, MD, MPH

has a financial relationship (Other) with AMLo Biosciences;.
has a financial relationship (Other) with Castle Biosciences;.

Vera Paulson, MD, PhD

has no relevant financial relationships to disclose at this time.

Rajeev Rajendra

has no relevant financial relationships to disclose at this time.

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.

Kartik Sehgal, MD

has a financial relationship (Other) with Exelexis, Inc.;.
has a financial relationship (Other) with MedScape;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Other) with Scholar Rock, Inc.;.
has a financial relationship (Travel) with Merck;.
has a financial relationship (Other) with Equinox Group, Inc.;.

Namrata Singh

has no relevant financial relationships to disclose at this time.

Sandy Srinivas, MBBS

has a financial relationship (Professional Services) with novartis;.
has a financial relationship (Professional Services) with merck;.
has a financial relationship (Professional Services) with jansen;.

Scott Tykodi, MD, PhD

has a financial relationship (Professional Services) with FirstWord;.
has a financial relationship (Grant Or Contract) with Exelixis;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Professional Services) with Targeted Oncology;.
has a financial relationship (Grant Or Contract) with AVEO Oncology;.
has a financial relationship (Professional Services) with Bristol Myers Squibb;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Pfizer;.

Yinghong Wang, MD PhD

has a financial relationship (Professional Services) with Sorriso;.

Paul White

has no relevant financial relationships to disclose at this time.

Available Credit

  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$150.00
Please login or register to take this course.

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.